Sugi Predict

Sugi Predict / Targets / CCND2

CCND2

G1/S-specific cyclin-D2 · P30279 · CCND2 on Sugi Atlas →

22,533 patent compounds predicted against CCND2, 14,530 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL189662 SCHEMBL189662 1.00 20/20
SCHEMBL1890595 SCHEMBL1890595 1.00 15/20
SCHEMBL189897 SCHEMBL189897 0.53 15/20
SCHEMBL190547 SCHEMBL190547 0.61 14/20
SCHEMBL660300 SCHEMBL660300 0.66 13/20
SCHEMBL190132 SCHEMBL190132 0.62 13/20
Palbociclib Palbociclib (SCHEMBL462630) 1.00 12/20
SCHEMBL660950 SCHEMBL660950 0.68 12/20
SCHEMBL188528 SCHEMBL188528 0.60 12/20
SCHEMBL188565 SCHEMBL188565 0.49 12/20
SCHEMBL1890597 SCHEMBL1890597 1.00 11/20
SCHEMBL660218 SCHEMBL660218 0.73 11/20
SCHEMBL659714 SCHEMBL659714 0.72 11/20
SCHEMBL659547 SCHEMBL659547 0.72 11/20
SCHEMBL1681080 SCHEMBL1681080 0.71 11/20
SCHEMBL660413 SCHEMBL660413 0.67 11/20
SCHEMBL660855 SCHEMBL660855 0.65 11/20
SCHEMBL659387 SCHEMBL659387 0.64 11/20
SCHEMBL659837 SCHEMBL659837 0.63 11/20
SCHEMBL189169 SCHEMBL189169 0.55 10/20

Clinical trials — most relevant to CCND2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas PHASE2RECRUITING
Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage PHASE2RECRUITING
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma PHASE1/PHASE2RECRUITING
Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma PHASE2COMPLETED
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) PHASE2COMPLETED
Cetuximab Plus Dalpicilib in Patients With HPV Negative, PD-1 Resistant R/M HNSCC PHASE2COMPLETED
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 PHASE2RECRUITING
Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B) PHASE2ACTIVE_NOT_RECRUITING
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma PHASE2COMPLETED
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer PHASE2RECRUITING
Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02) PHASE2UNKNOWN
A Study of Abemaciclib in Recurrent Glioblastoma PHASE2ACTIVE_NOT_RECRUITING
Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations PHASE2UNKNOWN
Abemaciclib + Pembrolizumab In Glioblastoma PHASE2WITHDRAWN
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype PHASE2RECRUITING
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms PHASE1COMPLETED
Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors PHASE1COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors PHASE1WITHDRAWN
Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients PHASE1COMPLETED
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors PHASE1COMPLETED
Study of FCN-437c in Patients With Advanced Solid Tumors PHASE1COMPLETED
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy nanUNKNOWN
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer nanCOMPLETED
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer nanUNKNOWN
Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a CCND2 binder may also engage these)

ProteinNameSimilarity
Q0P5D3 — 1.000 Q0P5D3 →
Q8WNW2 — 1.000 Q8WNW2 →
Q04827 — 1.000 Q04827 →
P30280 — 0.998 P30280 →
P53782 — 0.997 P53782 →
Q90459 — 0.995 Q90459 →
P49706 — 0.994 P49706 →
CCND1 G1/S-specific cyclin-D1 0.993 landscape →
P25322 — 0.993 P25322 →
Q2KI22 — 0.993 Q2KI22 →
Q64HP0 — 0.992 Q64HP0 →
P39948 — 0.992 P39948 →
Q5R6J5 — 0.991 Q5R6J5 →
P55169 — 0.991 P55169 →
Q52QT8 — 0.986 Q52QT8 →
P50755 — 0.986 P50755 →
P30282 — 0.985 P30282 →
Q16589 — 0.984 Q16589 →
Q32NM1 — 0.982 Q32NM1 →
P48961 — 0.981 P48961 →
CCND3 G1/S-specific cyclin-D3 0.981 landscape →
P51945 — 0.981 P51945 →
Q5E9I1 — 0.980 Q5E9I1 →
CCNE1 G1/S-specific cyclin-E1 0.980 landscape →
P51959 — 0.980 P51959 →
Q3MHH5 — 0.980 Q3MHH5 →
P39950 — 0.978 P39950 →
CCNE2 G1/S-specific cyclin-E2 0.978 landscape →
Q5R5D0 — 0.978 Q5R5D0 →
Q9D995 — 0.978 Q9D995 →